Download PDF
kleintier konkret 2014; 17(5): 20-25
DOI: 10.1055/s-0034-1384410
hund
onkologie
Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Canines malignes Lymphom – Pro und Contra von Prednisolon in der Initialtherapie

Kirsten Spellmeyer
Maurice Bob – Tierarztpraxis am Lietzenseepark GmbH
› Author Affiliations
Further Information

Publication History

Publication Date:
14 November 2014 (online)

Also available at
   Permissions and Reprints All articles of this category

Das maligne Lymphom zählt bei Hunden zu den häufigsten hämatopoetischen Tumorerkrankungen. Als Therapieansatz sind Chemotherapieprotokolle gebräuchlich; sie können die Lebenszeit der Patienten signifikant verlängern. Herkömmlich wird Prednisolon initial in hohen Dosen eingesetzt. Vor allem großrassige Hunde sprechen darauf häufig mit erheblichen Nebenwirkungen an. Anhand von 3 Hunden mit multizentrischem B-Zell-Lymphom konnte gezeigt werden, dass eine ebenso schnelle Remission auch ohne initiale Prednisolongabe zu erzielen ist. Der Verzicht auf Prednisolon verbessert – bei vergleichbarer Überlebenszeit – das Ansprechen auf das Rezidivprotokoll.

 

  • Literatur

  • 1 Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study. J Am Vet Med Hosp Assoc 2000; 36 (5): 404-409
    Google Scholar
  • 2 Chun R, Garrett LD, Vail MD. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000; 14 (2): 120-124
    CrossrefGoogle Scholar
  • 3 Comazzi S, Gelain ME, Spagnolo V et al. Flow cytometric patterns in blood from dogs with non-neoplastic and neoplastic hematologic diseases using double labeling for CD 18 and CD 45. Vet Clin Pathol 2006; 35 (1): 47-54
    CrossrefGoogle Scholar
  • 4 Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisolone: I. Treatment in dogs. J Am Anim Hosp Assoc 1983; 19: 159-165
    Google Scholar
  • 5 Dobson JM, Blackwood LB, McInnes EF et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 2001; 42 (8): 377-384
    CrossrefGoogle Scholar
  • 6 Dorn CR, Taylor DO, Schneider R. The epidemiologie of canine leukemia and lymphoma. Bibl Haematol 1970; 36: 403-415
    Google Scholar
  • 7 Dorn CR, Taylor DO, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res 1967; 28 (125): 993-1001
    Google Scholar
  • 8 Ettinger SN. Principles of treatment for canine lymphoma. Clin Tech Small Anim Pract 2003; 18 (2): 92-97
    CrossrefGoogle Scholar
  • 9 Garrett LD, Thamm DH, Chun R et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16 (6): 704-709
    CrossrefGoogle Scholar
  • 10 Hosoya K, Kisseberth WC, Lord LK et al. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. J Vet Intern Med 2007; 21 (6): 1355-1363
    CrossrefGoogle Scholar
  • 11 Keller ET, MacEwen EG, Rosenthal RC et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993; 7 (5): 289-295
    CrossrefGoogle Scholar
  • 12 Kessler M, Kandel B. Chemotherapie des malignen Lymphoms beim Hund: Ergebnisse und Erfahrungen mit dem Hofheimer Protokoll bei 57 Patienten. Kleintierprax 2004; 49: 349-358
    Google Scholar
  • 13 Madewell BR, Theilen GH. Hematopoietic neoplasms, sarkomas and related conditions. In: Theilen GH, Madewell BR, eds. Veterinary cancer medicine. 2. Aufl. Philadelphia: Lea and Fiebinger; 1987: 101-104
    CrossrefGoogle Scholar
  • 14 Madewell BR, Feldmann BF. Characterization of anemias associated with neoplasia in small animals. J Am Vet Med Assoc 1980; 176 (5): 419-425
    Google Scholar
  • 15 Mealey KL, Bentjen SA, Gay JM et al. Dexamethasone treatment of a canine, but not human, tumor cell line increases chemoresistance independent of P-glycoprotein and multidrug resistance-related protein expression. Vet Comp Oncol 2003; 1 (2): 67-75
    CrossrefGoogle Scholar
  • 16 Modiano JF, Breen M, Burnett RC et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005; 65 (13): 5654-5661
    CrossrefGoogle Scholar
  • 17 Moulton JE, Harvey JW. Tumors of lymphoid and hematopoietic tissue. In: Moulton JE, ed. Tumors of domestic animals. 3rd ed. California: University of California Press; 1990
    Google Scholar
  • 18 Piek CJ, Ruttemann GR, Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemo-therapie protocol in dogs with malignant lymphoma. Vet Q 1999; 21 (2): 44-49
    CrossrefGoogle Scholar
  • 19 Price GS, Page RL, Fischer BM et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapie in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991; 5 (5): 259-262
    CrossrefGoogle Scholar
  • 20 Priester WA. Canine lymphoma: relative risk in the boxer breed. J Natl Cancer Inst 1967; 39 (5): 833-845
    Google Scholar
  • 21 Simon D, Nolte I, Eberle N et al. Treatment of dogs with lymphoma using 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006; 20 (4): 948-954
    CrossrefGoogle Scholar
  • 22 Teske E. Hämatopoetische Tumoren. In: Kessler M, Hrsg. Kleintieronkologie. Stuttgart: Enke; 2013: 493-502
    Google Scholar
  • 23 Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin’s lymphoma. Vet Q 1994; 16 (4): 209-219
    CrossrefGoogle Scholar
  • 24 Teske E, Wisman P, Moore PF et al. Histologic classification and immunophenotyping of canine non-Hodgin’s lymphomas: unexpected high frequency of T-cell lymphomas with B-cell morphology. Exp Hematol 1994; 22 (12): 1179-1187
    Google Scholar
  • 25 Teske E, Ruttemann GR, Van Heerde P et al. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodginʼs lymphoma. Eur J Cancer 1990; 26 (8): 891-895
    CrossrefGoogle Scholar
  • 26 Vail DM, Pinkerton ME, Young KM. Hematopoietic tumors. In: Withrow SJ, Vail DM, Rodney LP, eds. Small Animal Clinical Oncology. 5th ed. St. Louis, Missouri: Elsevier; 2013: 608-663
    Google Scholar
  • 27 Valli VE, San Myint M, Barthel A et al. Classi-fication of canine malignant lymphomas according to the World Health Organization criteria. Vet Patholog 2011; 48 (1): 198-211
    Google Scholar
  • 28 Villamil JA, Henry CJ, Hahn AW et al. Hormonal and sex impact on the epidemiologie of canine lymphoma. J Cancer Epidem 2009; Article ID 591753, Epub 2010
    Google Scholar